Furthermore, because PSA is not cancer-specific, it can increase due to recurrent benign prostatic tissue that may grow following other curative-intent treatments, such as external beam radiotherapy (EBRT) or minimally invasive therapies, and, on rare occasions, residual benign prostatic tissue post-RP, leading to false positives [8,9]. The gene discussed is KLK3; the disease is cancer.